OPUS GENETICS INC (IRD) Stock Price, Quote, News and Overview
NASDAQ:IRD - Nasdaq - US67577R1023 - Common Stock - Currency: USD
IRD Quote, Performance and Key Statistics
1.21
+0.01 (+0.83%)
The current stock price of IRD is 1.21 USD. In the past month the price increased by 24.72%.
IRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.58 | 337.08B | ||
| AMGN | AMGEN INC | 14.86 | 165.91B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 140.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 121.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.74 | 60.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.77B | ||
| ARGX | ARGENX SE - ADR | 102.91 | 36.13B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.56 | 32.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.48B | ||
| INSM | INSMED INC | N/A | 19.64B | ||
| BIIB | BIOGEN INC | 8.38 | 19.43B |
Related stock screener links
About IRD
Company Profile
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Company Info
OPUS GENETICS INC
8 Davis Drive, Suite 220
Durham NORTH CAROLINA US
Employees: 18
Phone: 12486819815
OPUS GENETICS INC / IRD FAQ
What is the stock price of OPUS GENETICS INC today?
The current stock price of IRD is 1.21 USD. The price increased by 0.83% in the last trading session.
What is the ticker symbol for OPUS GENETICS INC stock?
The exchange symbol of OPUS GENETICS INC is IRD and it is listed on the Nasdaq exchange.
On which exchange is IRD stock listed?
IRD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OPUS GENETICS INC stock?
7 analysts have analysed IRD and the average price target is 7.96 USD. This implies a price increase of 557.52% is expected in the next year compared to the current price of 1.21. Check the OPUS GENETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OPUS GENETICS INC worth?
OPUS GENETICS INC (IRD) has a market capitalization of 72.19M USD. This makes IRD a Micro Cap stock.
How many employees does OPUS GENETICS INC have?
OPUS GENETICS INC (IRD) currently has 18 employees.
What are the support and resistance levels for OPUS GENETICS INC (IRD) stock?
OPUS GENETICS INC (IRD) has a support level at 1.1 and a resistance level at 1.22. Check the full technical report for a detailed analysis of IRD support and resistance levels.
Is OPUS GENETICS INC (IRD) expected to grow?
The Revenue of OPUS GENETICS INC (IRD) is expected to grow by 81.34% in the next year. Check the estimates tab for more information on the IRD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OPUS GENETICS INC (IRD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IRD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IRD, evaluating the profitability, health, valuation and growth aspects
- OPUS GENETICS INC (IRD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OPUS GENETICS INC (IRD) Sales and EPS estimates to see what analysts future expectations are.
- OPUS GENETICS INC (IRD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OPUS GENETICS INC (IRD) Insider and Institutional Ownership to learn about the owners and their transactions.
- OPUS GENETICS INC (IRD) Stock Chart to make your own analysis
- OPUS GENETICS INC (IRD) Latest news and press-releases to stay up to date.
Does OPUS GENETICS INC (IRD) stock pay dividends?
IRD does not pay a dividend.
When does OPUS GENETICS INC (IRD) report earnings?
OPUS GENETICS INC (IRD) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of OPUS GENETICS INC (IRD)?
OPUS GENETICS INC (IRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).
What is the Short Interest ratio of OPUS GENETICS INC (IRD) stock?
The outstanding short interest for OPUS GENETICS INC (IRD) is 2.44% of its float. Check the ownership tab for more information on the IRD short interest.
IRD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IRD.
IRD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IRD. The financial health of IRD is average, but there are quite some concerns on its profitability.
IRD Financial Highlights
Over the last trailing twelve months IRD reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -114.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.7% | ||
| ROE | -245.11% | ||
| Debt/Equity | 0 |
IRD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to IRD. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 22.26% and a revenue growth 81.34% for IRD